BlueBlood Ventures (BVL) Reports Negative Revenue and Widening Loss in Q4 FY26
The financial services firm posted a quarterly loss as its revenue turned negative, capping a volatile year of growth and regulatory challenges.
BlueBlood Ventures ended FY26 with a quarter of negative revenue and a wider loss, contrasting sharply with strong annual growth. The company's shares remain suspended, and auditors flagged concerns over significant investments.
For BlueBlood Ventures, a financial services firm in a prolonged trading suspension, the final quarter of FY26 was a sharp reversal. After a strong first half, the March quarter saw revenue turn negative and losses widen, highlighting the volatile nature of its investment-led business model.
The quarterly scorecard shows a stark contrast to the prior period. Revenue fell to -₹0.22 crore from ₹1.01 crore in Q2 FY26, while profit swung to a loss of -₹0.14 crore from a profit of ₹0.17 crore. The reported net profit margin of 63.6% is a mathematical artifact of negative revenue, not a sign of profitability.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ4 FY26 | Same quarter LYQ4 FY25 |
|---|---|---|
| Revenue (₹ Cr) | -0.22YoY -222% | 0.18 |
| Profit (₹ Cr) | -0.14 | 0.00 |
| Net Profit Margin (%) | 63.6 | 0.0 |
The Volatility of an Investment Portfolio
The negative revenue figure points to mark-to-market losses or valuation adjustments on the company's equity investments. According to its annual report, BlueBlood Ventures holds a portfolio including shares in Everest, Neelanchal, and Zero Coupon Convertible Debentures in Devoted Construction Ltd. valued at ₹1155 lakhs. The quarter's performance suggests this portfolio suffered a write-down.
This volatility overshadows a stronger full-year picture. For FY26, revenue more than doubled to ₹1.01 crore, and profit jumped over 400% to ₹0.03 crore, as reported by scanx.trade. The annual growth was driven by a 58% increase in revenue from operations, though other expenses surged due to business promotion costs.
Regulatory Hurdles Cloud the Outlook
The company's ability to capitalize on any operational improvement is severely constrained. Trading in its shares has been suspended on the BSE since November 2022 due to regulatory non-compliance. A delisting waiver application is pending, creating significant uncertainty for shareholders.
Auditors from KRA & Associates, cited by scanx.trade, highlighted an emphasis of matter regarding ₹1155 lakhs worth of Zero Optional Convertible Debentures that were wrongly transferred. Management optimism, rather than confirmed settlements, underpins the recoverability of another ₹6346 lakhs in long-term loans and advances.
Key Points
- The Q4 FY26 loss was driven by negative revenue, likely from investment portfolio markdowns, reversing the profit seen in Q2.
- Full-year FY26 performance showed strong growth, with revenue doubling and profit rising over 400%, though from a very low base.
- A prolonged trading suspension and pending delisting proceedings present major near-term risks to shareholder value realization.
- Auditors flagged significant concerns over the recoverability of large investments and advances on the balance sheet.
Hexa Perspective
This quarter underscores the fundamental challenge of analyzing BlueBlood Ventures: its financials are a story of two halves. The annual figures show progress in building a tiny operational business, but the quarterly volatility reveals a balance sheet heavily exposed to illiquid and potentially impaired investments.
The path forward is gated by regulatory resolution. Until the trading suspension is lifted and the delisting notice resolved, the company's strategic shift and any operational gains remain academic for public market investors. The high valuation premium, with a P/E of 100.6 against an industry average of 22.0, seems disconnected from these palpable execution and compliance risks.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.
